2013
DOI: 10.1097/jto.0b013e318292bdef
|View full text |Cite
|
Sign up to set email alerts
|

Lung Cancer Detection with Digital Chest Tomosynthesis: Baseline Results from the Observational Study SOS

Abstract: The detection rate of noncalcified lung nodules for tomosynthesis was comparable with rates reported for CT. A small subgroup underwent low-dosage CT and entered a follow-up program. Overall, lung cancer was detected in approximately 1% of cases. Digital chest tomosynthesis holds promise as a first-line lung cancer screening tool.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
28
0
2

Year Published

2014
2014
2023
2023

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 38 publications
(32 citation statements)
references
References 16 publications
(12 reference statements)
1
28
0
2
Order By: Relevance
“…[24][25][26] However, the inability to extract the number of true-positives, false-positives, true-negatives and false-negatives could be a significant drawback to our study, as this is essential when assessing the appropriateness of utilizing a technique for clinical use. In our meta-analysis, some studies which used CT as the reference standard did not suggest the truenegative number, because they demonstrated only the true-positive number of nodules detected with DTS and chest radiography among nodules detected with CT. 13,22,23 In other studies, sensitivity was estimated on a per-lesion basis, but specificity was exclusively estimated on per-patient basis. 9,11,21,27 Thus, we inevitably analyzed the detection rate from lesion-based data because we considered those information could be significant for evaluating the diagnostic value for the detection of pulmonary nodule despite definite limitations.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…[24][25][26] However, the inability to extract the number of true-positives, false-positives, true-negatives and false-negatives could be a significant drawback to our study, as this is essential when assessing the appropriateness of utilizing a technique for clinical use. In our meta-analysis, some studies which used CT as the reference standard did not suggest the truenegative number, because they demonstrated only the true-positive number of nodules detected with DTS and chest radiography among nodules detected with CT. 13,22,23 In other studies, sensitivity was estimated on a per-lesion basis, but specificity was exclusively estimated on per-patient basis. 9,11,21,27 Thus, we inevitably analyzed the detection rate from lesion-based data because we considered those information could be significant for evaluating the diagnostic value for the detection of pulmonary nodule despite definite limitations.…”
Section: Discussionmentioning
confidence: 99%
“…9,11,13,[21][22][23] However, we could extract the total numbers of true positives and the total number of pulmonary nodules, which allowed us to calculate and analyze detection rates. Thus, we identified 7 studies (1017 patients) that presented per-patient results 10,12,[17][18][19][20][21] and 10 studies that presented per-lesion results (2159 lesions) 9,11,13,[21][22][23][24][25][26][27] for meta-analysis. Only one study included both per-patient-and per-lesion-based data.…”
Section: Study Characteristics and Patient Populationsmentioning
confidence: 99%
“…A digitális tomoszintézis egyik előnye a CT-szűréssel szemben, hogy kisebb az erőforrásigénye mind a szakemberek, mind a költségek vonatkozásában, emellett kevesebb a sugárzáshoz köthető káros hatása is [45]. A szűrés bizonytalansága azonban magasabb, így a DTS-szűrés mint első vonalas beavatkozás egyelőre nem használható.…”
Section: Megbeszélés éS Limitációkunclassified
“…[22][23][24] Finally, owing to the very low dose of DTS, it has been suggested as a suitable technique for lung cancer screening. 25 Three DTS systems for chest tomosynthesis currently exist. The studies described above were performed using the systems from Shimadzu Corporation (Kyoto, Japan) and GE Healthcare (Chalfont St Giles, UK).…”
Section: Introductionmentioning
confidence: 99%